HomeWhat is PsoriasisTreatmentScientific MeetingsRelated LinksPsoriasis ArticlesContact usما هي الصدفية

Topical Treatments:

Systemic Treatments:

Biological Treatments:






Ustekinumab (trade name Stelara) is a human interleukin-12 and -3 antagonist that is approved by the FDA for the treatment of adult patients 18 years and older with moderate-to-severe chronic plaque psoriasis.

It is administered as a subcutaneous injection once a month for 2 months, and subsequently every 12 weeks.

The rapid onset of action and convenient dosing schedule of ustekinumab make it an attractive preference for treatment of severe or rapidly progressive psoriasis.